Trial Profile
A phase 3, 54-week, open-label study to assess safety and efficacy of Levodopa/carbidopa monotherapy in patients with Advanced Parkinson's Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Jul 2018
Price :
$35
*
At a glance
- Drugs Levodopa/carbidopa (Primary) ; Levodopa/carbidopa
- Indications Parkinson's disease
- Focus Adverse reactions; Therapeutic Use
- 19 Jun 2018 Results presented at the 4th Congress of the European Academy of Neurology
- 11 May 2018 New trial record
- 27 Apr 2018 Results presented at the 70th Annual Meeting of the American Academy of Neurology